MEA Nucleic Acid Labelling Market

MEA Nucleic Acid Labelling Market Size (2024 to 2029)

The Nucleic Acid Labelling Market size in the Middle East & Africa was valued at USD 131.27  Million in 2024 and estimated to grow at a CAGR of 8.97% to reach USD 201.69 million by USD 2029.

Factors such as rising healthcare expenditure, increased funding for genomics and disease diagnosis research, and increasing demand for personalized healthcare are driving the Middle East and Africa nucleic acid labeling market. For example, scientists can modify drugs to be more effective, improving treatment outcomes using genomic information. Furthermore, by categorizing diseases based on genetic variation rather than symptoms, this technique might be used to discover and diagnose diseases in a targeted manner, attracting many patients and promoting the nucleic acid labelling sector.

One of the other key drivers of the nucleic acid labelling market in the Middle East and Africa during the projected period is the rising incidence of chronic diseases leading to diabetes and other cardiovascular diseases and patient demand for tailored medications.

The genomes of numerous species, from bacteria to humans, have been entirely sequenced thanks to the astonishing advancement of sequencing technology. Furthermore, the recent introduction of Next Generation Sequencing (NGS) methods, which previously followed standard capillary sequencing methods, has substantially improved the sequencing pace. NGS technologies analyze various quantities and types of DNA libraries in a more precise, quick, and economical manner and in a more generalized manner, which is propelling the industry. In addition, NGS offers powerful tools for uncovering vital biological information such as whole genome sequences, DNA protein variants, and interactions and for diagnostic and therapeutic applications, assisting the Middle East and Africa market's growth.

However, the government's strict rules and regulations governing the approval of newly manufactured reference products are currently inhibiting market expansion in this region. A scarcity of competent personnel further hampers the market's demand to supervise procedures. The cost of installing and maintaining total equipment is quite high, and market developers have found this to be a difficult task. During the projection period, the nucleic acid labelling industry would face considerable headwinds due to a scarcity of competent professionals. Furthermore, due to a shortage of skilled professionals familiar with the interpretation of HCV test findings, it isn't easy to know when further specialized testing should be performed and which tests should be considered.

This research report on the MEA Nucleic Acid Labelling Market has been segmented and sub-segmented into the following categories:

By Product: 

• Reagents and Kits
• Services

By Labelling Technique: 

• PCR
• Nick Translation
• Random Primer
• In-Vitro Transcription
• Reverse Transcription

By Application: 

• DNA Sequencing
• PCR
• Fluorescence in Situ Hybridization (FISH)
• Microarrays
• Blotting
• In-Situ Hybridization

By End Users: 

• Diagnostic Centres
• Research Centres
• Hospitals

By Country: 

• KSA
• UAE
• Israel
• rest of GCC countries
• South Africa
• Ethiopia
• Kenya
• Egypt
• Sudan
• rest of MEA

Initiatives by the governmental and private groups are propelling the expansion of the nucleic acid labelling sector in the Middle East and Africa. The growing popularity of designing synthetic genomes using various technologies accessible in the biotechnology area primarily meets the market demand. In addition, increasing government assistance by modifying schemes in favor of regular people provides market actors with growth chances. An increase in disposable income is another aspect influencing market demand. Furthermore, the business is being driven by a shift in public perception of personalized medicine.

Saudi Arabia is expected to dominate the Middle East and Africa Nucleic Acid Labelling market during the projected period. Public and private sector initiatives are accelerating the expansion of the nucleic acid labelling industry. In addition, the growing popularity of designing synthetic genomes using various technologies accessible in the biotechnology area is primarily to meet market demand.

Israel is predicted to hold the most significant share of the Middle East and Africa nucleic acid labeling market after Saudi Arabia during the forecast period. The primary growth driver has increased investments in research and development centers to introduce new products. In addition, the market's demand is being fueled by a growing focus on genomics.

KEY MARKET PLAYERS:

Companies playing a leading role in the Middle East & Africa nucleic acid labelling market profiled in the report are Thermo Fisher Scientific, New England Biolabs, PerkinElmer, F. Hoffmann La-Roche AG, General Electric Company, Merck KGaA, Enzo Biochem, Promega Corporation, Vector Laboratories, and Agilent Technologies.